-
The Upstream and Downstream products of Carbetocin Acetate
Time of Update: 2023-04-29
The market for Carbetocin Acetate and its downstream products is expected to grow at a steady pace over the next few years, driven by the increasing demand for contraceptives, hormone replacement therapy drugs, and drugs used to treat infertility.
-
Elevated transaminases = impaired liver function
Time of Update: 2022-08-12
For example, the determination of ALT activity can diagnose whether the liver function is normal or not, and the serum ALT activity of patients with acute hepatitis can be significantly higher than that of normal persons; while the determination of AST activity is helpful for the diagnosis of heart disease, and the serum AST activity in myocardial infarction shows that rise .
-
The first CD19-targeted ADC therapy launched Phase 3 clinical joint development supported by Hillhouse
Time of Update: 2022-03-07
According to public information, Lonca, developed by ADC Therapeutics, is the first FDA-approved antibody-drug conjugate targeting CD19, which can be used as a single agent for the treatment of adult patients with relapsed/refractory large B-cell lymphoma .
-
Shark antibody-like protein can neutralize COVID-19 virus
Time of Update: 2021-12-27
Source: Bryce Richter/University of Wisconsin-MadisonAccording to a new study published on December 16, small, unique antibody-like proteins called VNARs—from the shark’s immune system—can prevent the virus that causes COVID-19, its variants, and related coronavirus infections Human cells .
-
The State Food and Drug Administration approves the marketing of Donafinil tosylate tablets
Time of Update: 2021-06-22
On June 9, the official website of the State Food and Drug Administration announced that the State Food and Drug Administration recently passed the priority review and approval procedure to approve the Class 1 innovative drug Donafenib Tosylate (trade name:) declared by Suzhou Zejing Biopharmaceutical Co.
-
International fund giants sharply increase their holdings of Hengrui Pharmaceuticals Sun Piaoyang personally denounces 316 million overweight new pharmaceutical companies
Time of Update: 2021-05-02
Many public funds have reduced their holdings of Hengrui Pharmaceuticals, but Oppenheimer Funds bucked the trend and increased their positions by nearly 20 million shares.
-
The ranking of proprietary Chinese medicines for respiratory system has changed, and 14 exclusive products "seize" TOP20
Time of Update: 2021-04-23
Among the TOP20 products, 6 products have sales of more than 100 million yuan; 14 are exclusive products, involving Yangtze River Beijing Haiyan Pharmaceutical, Tianjin Hongri Pharmaceutical, Jichuan Pharmaceutical Group, Beijing Yiling Pharmaceutical and other companies In terms of growth rate, Shuanghuanglian oral liquid and Lianhua Qingwen granules both increased by more than 50% year-on-year.
-
The first imitation of tens of billions of blockbuster varieties is declared for listing, and the market is fierce
Time of Update: 2021-04-18
. Medical Network News on April 13 Ten billion market, the first imitation is nearly Recently, CDE's official website showed that Simcere's application for the listing of Ibrutinib capsules was officially accepted by the State Food and Drug Administration, becoming the first generic drug of Ibrutinib submitted for marketing in China, and it is expected to realize the first imitation.
-
The global cancer drug giant ranks TOP10
Time of Update: 2021-03-19
S. dollars (approximately RMB 93 billion), contributing 33% of the total revenue and 91% of the oncology business.
The CD38 monoclonal antibody drug daratumomab and the BTK inhibitor ibrutinib are Johnson & Johnson's two major oncology products, which together contribute more than 8 billion U.
-
Hope to fill the blanks! Anti-epileptic "old medicine" to establish "new work
Time of Update: 2021-02-23
The results come from Xiamen University's National Key Laboratory of Cell Stress, Xiamen University School of Neuroscience Research Institute Professor Wang Xin team, researchers through a series of studies, confirmed that the clinical anti-epileptic drug valproic acid, can greatly improve a new type of resymnant disorder and small brain atrophy disease, the discovery has strong clinical conversion application value, is expected to fill the gap in the field of genetic co-eclampsia treatment.
-
How to treat metastasis grape membrane melanoma? FDA awards tebentafusp 'breakthrough therapy title
Time of Update: 2021-02-23
Immunocore, a late-stage biotechnology company dedicated to developing new T-cell-specific (TCR) dual-specific immunotherapy, announced today that the U.S. Food and Drug Administration (FDA) has awarded tebentafusp (IMCgp100) a "breakthrough therapy title" (BTD) for the treatment of adult patients with non-removable or metastasis staphylocolum melanoma (mUM).
-
The Drug Administration has strengthened the management of Chinese medicine injections into a province's key monitoring scope
Time of Update: 2021-02-07
The State Health and Safety Commission and other departments require Chinese medicine injections to be prescribed separately on July 10, the National Health and Health Commission, the Administration of Traditional Chinese Medicine, and the Logistics support department of the Central Military Commission jointly issued the Notice on the Prescription Audit Specifications of Medical Institutions.
-
Takeda Dazeyou was approved to enter China to fill the domestic HAE long-term non-targeted treatment gap
Time of Update: 2020-12-19
Dazeyou® (Lanaliyu monoantigenic injection) is currently the world's only monoclonal antibody (mAb) drug for hereditary angioedema, can reduce the number of recurrent episodes of edema in patients, prevent asphyxiation caused by fatal throat edema, improve the quality of life of patients and their families, fill the gap in China HAE long-term non-targeted treatment.
-
Q3 A total of 25 new drugs were approved for sale, what are the highlights
Time of Update: 2020-11-11
In addition, the new drugs approved in the quarter included a number of rare disease treatment drugs, such as the Fabre disease treatment drug agagaglyzyme α injection with a strong solution, the treatment of Hunter syndrome Ado sulfate enzyme β injection, as well as Dongpei Pharmaceuticals brought the rare disease drug Senaigmin eye drops.
-
Chinese gynaecological experts with new advances in ovarian cancer research landed in ESMO, patients have a new standard of treatment
Time of Update: 2020-10-12
This is the first time in recent years that a clinical study of local ovarian cancer PARP inhibitors, led by Chinese clinical experts, has published its core results to international scholars at the ESMO Conference in the form of a full oral report, and the first time in the world that the individualized starting dose of Nirapali has been used in patients with platinum-sensitive relapsed ovarian cancer.
